Literature DB >> 15005244

Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.

Yoshiaki Okuma1, Kazushige Kiguchi, Yutaka Koshitaka, Asami Okamura, Isamu Ishiwata, Haruhiro Kondo, Bunpei Ishizuka, Mamoru Tadokoro.   

Abstract

Despite recent advances in the application of chemotherapy to ovarian cancer, the development of alternative therapies that retain activity against drug-resistant-tumors remains a high priority. We analyzed a number of cultured ovarian cancer cell lines of different tissue types for the presence or absence of sensitivity to various anticancer drugs as well as expression patterns of oncogene products (erbB-2, EGFR, bcl-2). As a result, we identified oncogene products that were related to resistance. Using 9 cultured cell lines of ovarian cancers (serous, mucinous, endometrioid, clear, undifferentiated), sensitivities to anticancer drugs were investigated using the MTT assay. The phenotypes of oncogene products expressed by the above cultured cell lines were analyzed by Western blotting. The oncogene products involved in resistance to anticancer drugs were identified by multivariate analysis. Positive correlation between the resistance to anticancer drugs and the oncogene products was obtained by multivariate analysis for (a) CDDP and erbB-2 (b) x p-16 and erbB-2, and (c) MMC and EGFR. Correlation between resistance to anticancer drugs and expression of certain oncogene products was obtained in ovarian cancers, suggesting that sensitivity to anticancer drugs could be predicated prior to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15005244     DOI: 10.1111/j.1749-0774.2003.tb00145.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  24 in total

1.  Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.

Authors:  J G Hengstler; J Lange; A Kett; N Dornhöfer; R Meinert; M Arand; P G Knapstein; R Becker; F Oesch; B Tanner
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 2.  The biochemistry of programmed cell death.

Authors:  G Kroemer; P Petit; N Zamzami; J L Vayssière; B Mignotte
Journal:  FASEB J       Date:  1995-10       Impact factor: 5.191

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.

Authors:  R A Britten; S Perdue; A Eshpeter; D Merriam
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

5.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

Authors:  M D Pegram; R S Finn; K Arzoo; M Beryt; R J Pietras; D J Slamon
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

6.  [Establishment and characterization of a cell line derived from mucinous cystadenocarcinoma of human ovary].

Authors:  Y Kidera; T Yoshimura; Y Ohkuma; T Iwasaka; H Sugimori
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1985-09

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cell cloning--with special reference to the stem cell of the tumor.

Authors:  S Nozawa; K Tsukazaki; M Sakayori; C H Jeng; R Iizuka
Journal:  Hum Cell       Date:  1988-12       Impact factor: 4.174

9.  EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value.

Authors:  H Meden; D Marx; T Raab; M Kron; A Schauer; W Kuhn
Journal:  J Obstet Gynaecol (Tokyo 1995)       Date:  1995-04

10.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

View more
  3 in total

1.  The value of serum bcl-2 levels in advanced epithelial ovarian cancer.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  New chemosensitivity test using a thermo-reversible gelation polymer for recurrent gynecologic cancer patients and a preliminary study of mechanisms of anticancer drug resistance.

Authors:  Tatsuru Ohara; Kazushige Kiguchi; Satoshi Tsukikawa; Sojiro Sato; Yoichi Kobayashi; Bunpei Ishizuka; Sunao Kubota
Journal:  Hum Cell       Date:  2005-09       Impact factor: 4.174

3.  Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents.

Authors:  Eriko Takatori; Tadahiro Shoji; Seisuke Kumagai; Takashi Sawai; Akira Kurose; Toru Sugiyama
Journal:  J Ovarian Res       Date:  2012-06-12       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.